PHARMACEUTICAL 2024

Genelux Corp
Rank 157 of 309



PHARMACEUTICAL 2024

Genelux Corp
Rank 157 of 309

The relative strengths and weaknesses of Genelux Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Genelux Corp compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 71% points.The greatest weakness of Genelux Corp is the variable Net Income, reducing the Economic Capital Ratio by 51% points.

The company's Economic Capital Ratio, given in the ranking table, is 212%, being 0.83% points below the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	24,203
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,554
Liabilities, Non-Current	1,866
Other Assets	2,520
Other Compr. Net Income	12
Other Expenses	0
Other Liabilities	0
Other Net Income	-4,132
Other Revenues	170
Property and Equipment	1,170
Research and Development	12,767
Selling, General and Administrative Expense	11,568

Output Variable	Value in 1000 USD
Assets	27,893
Liabilities	8,420
Expenses	24,335
Revenues	170
Stockholders Equity	19,473
Net Income	-28,297
Comprehensive Net Income	-28,291
BaseVar	32,481
ECR before LimitedLiability	78%
Economic Capital Ratio	212%